We have located links that may give you full text access.
Effect of flavonoid-rich extract of Tamarix articulata Vahl. on glucose and lipid metabolism in normal and diabetic rats.
Cardiovascular & Hematological Agents in Medicinal Chemistry 2018 December 12
OBJECTIVE: The present study was carried out in order to evaluate the antidiabetic and antihyperlipidemic potential of flavonoid-rich extract of Tamarix articulata (FRETA) in both normal and streptozotocin (STZ)-induced diabetic rats.
MATERIAL AND METHODS: Normal and diabetic rats were treated with the FRETA for 7 days. At the end of treatment, a range of parameters were tested including blood lipid profile, histopathological changes in both liver and pancreas and oral glucose tolerance test (OGTT).
RESULTS: The blood glucose levels were lowered in both normal and diabetic rats treated with FRETA. Single oral administration of FRETA reduced blood glucose levels significantly in both normal and diabetic rats six hours after administration (P<0.001; P<0.0001 respectively). Furthermore, blood glucose levels were decreased significantly (P<0.0001) in diabetic rats after 7 days of treatment. According to the oral glucose tolerance test, the FRETA (5 mg/kg) was shown to prevent significantly the increase on blood glucose levels in diabetic treated rats. In addition, FRETA (5 mg/kg) showed a strong hypolipidemic effect both in normal and STZ rats after 7 days of once daily oral treatment. FRETA induced a significant decrease of plasma triglyceride and total cholesterol concentrations both in normal and diabetic rats. In contrast, plasma HDL-c levels were increased significantly (P<0.0001) both in normal and diabetic rats. In addition, FRETA showed a remarkable in vitro antioxidant activity and revealed inhibitory concentration of 50% of free radicals (IC50) of 31.92 μg/ml.
CONCLUSION: In diabetic rats flavonoids from Tamarix articulata showed antidiabetic and hypolipidemic activities.
MATERIAL AND METHODS: Normal and diabetic rats were treated with the FRETA for 7 days. At the end of treatment, a range of parameters were tested including blood lipid profile, histopathological changes in both liver and pancreas and oral glucose tolerance test (OGTT).
RESULTS: The blood glucose levels were lowered in both normal and diabetic rats treated with FRETA. Single oral administration of FRETA reduced blood glucose levels significantly in both normal and diabetic rats six hours after administration (P<0.001; P<0.0001 respectively). Furthermore, blood glucose levels were decreased significantly (P<0.0001) in diabetic rats after 7 days of treatment. According to the oral glucose tolerance test, the FRETA (5 mg/kg) was shown to prevent significantly the increase on blood glucose levels in diabetic treated rats. In addition, FRETA (5 mg/kg) showed a strong hypolipidemic effect both in normal and STZ rats after 7 days of once daily oral treatment. FRETA induced a significant decrease of plasma triglyceride and total cholesterol concentrations both in normal and diabetic rats. In contrast, plasma HDL-c levels were increased significantly (P<0.0001) both in normal and diabetic rats. In addition, FRETA showed a remarkable in vitro antioxidant activity and revealed inhibitory concentration of 50% of free radicals (IC50) of 31.92 μg/ml.
CONCLUSION: In diabetic rats flavonoids from Tamarix articulata showed antidiabetic and hypolipidemic activities.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app